There's been lots of hullaballoo surrounding Sanofi and MannKind's launch of inhaled insulin Afrezza, but for the arrival of the pair's first DTC campaign? Not so much.
Surprise! It's a DTC campaign for Sanofi and Mannkind's Afrezza. The low-key ad launch of "Surprise, It's Insulin" came with little fanfare, unlike the media and industry scuttlebutt surrounding the drug itself, which has been closely watched and analyzed for more than a year.
Olivier Brandicourt, CEO of Sanofi, gave his thoughts on the July 30 earnings call about trying to launch a simplification program in the midst of high-profile global rollouts, competition and dealmaking. He also picked one contest to watch in Japan that may be a good gauge of the company's performance on all counts.
China's ZAI Lab has in-licensed a novel multi-kinase inhibitor aimed at a non-small cell lung cancer candidate from Sanofi as the firm led by well-known biotech executive Samantha Du builds its on deep Greater China trial and regulatory experience.
Sanofi's new CEO, Olivier Brandicourt, has a new company structure he is trotting out, a new potentially hot cholesterol-lowering drug to launch and now is able to take credit for a full quarter's worth of financial results that outperformed the street's best guesses. He even said today that Sanofi may be ready to do some wheeling and dealing, having so far stayed out of the M&A melee that has been going on all year.
Last week, Sanofi revealed a $14,600 sticker for new PCSK9 med Praluent that far exceeded the price tag analysts expected. And unsurprisingly, leading PBM and vocal price critic Express Scripts is none too thrilled about it.
As it works to introduce its dengue vaccine in endemic countries around the world, Sanofi Pasteur this week touted efficacy results from two Phase III studies in a move to help build the case for wide uptake.
Sanofi has gotten a bit of positive reinforcement in its efforts to revive its diabetes business in the U.S. Experimental combo med LixiLan has thrown off some promising results, hitting its primary goal in a late-stage trial.
Sanofi's diabetes business--long the company's growth driver--is in for a slowdown over the next few years, and any sales expansion the French drugmaker sees will depend, in part, on new U.S. launches. Now, experimental combo med LixiLan is one step closer to joining that launch group after nailing its main goal in a late-stage trial.
Sanofi's combination of a Type 2 diabetes treatment and a long-acting insulin met its main goal in a Phase III trial, the company said, setting up an FDA application later this year.